The impact of E-cadherin expression on non-small cell lung cancer survival: a meta-analysis

详细信息    查看全文

• 作者：Ying Wu (1)
  Hong-Bing Liu (2)
  Ming Ding (1)
  Jian-Nan Liu (1)
  Ping Zhan (3)
  Xiao-Su Fu (4)
  Gan Lu (1) lugan0121@163.com
• 关键词：E ; cadherin – ; Meta ; analysis – ; Non ; small cell lung cancer – ; Prognosis – ; Survival
• 刊名：Molecular Biology Reports
• 出版年：2012
• 出版时间：October 2012
• 年：2012
• 卷：39
• 期：10
• 页码：9621-9628
• 全文大小：285.6 KB
• 参考文献：1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212–236. doi:
  2. Reis L, Eisner M, Kosary C (2008) SEER cancer statistics review, 1975–2002. National Cancer Institute, Bethesda
  3. Navada S, Lai P, Schwartz A, Kalemkerian G (2006) Temporal trends in small cell lung cancer: analysis of the national surveillance, epidemiology, and end–results (SEER) database. J Clin Oncol 24(18 suppl):7082
  4. Edge SB, Compton CC (2010) The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474
  5. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P et al (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European lung cancer working party. J Clin Oncol 13(5):1221–1230
  6. Christofori G (2006) New signals from the invasive front. Nature 441(7092):444–450. doi:
  7. Pignatelli M, Vessey CJ (1994) Adhesion molecules: novel molecular tools in tumor pathology. Hum Pathol 25(9):849–856
  8. Goodwin M, Yap AS (2004) Classical cadherin adhesion molecules: coordinating cell adhesion, signaling and the cytoskeleton. J Mol Histol 35(8–9):839–844. doi:
  9. Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4(2):118–132. doi:
  10. Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, Oyama T (2010) Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 30(7):2513–2517
  11. Behrens J, Mareel MM, Van Roy FM, Birchmeier W (1989) Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell–cell adhesion. J Cell Biol 108(6):2435–2447
  12. Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, Iihara K, Doki Y, Hirano S, Takeichi M et al (1991) Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 139(1):17–23
  13. Shiozaki H, Oka H, Inoue M, Tamura S, Monden M (1996) E-cadherin mediated adhesion system in cancer cells. Cancer 77(8 Suppl):1605–1613. doi:
  14. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ (1996) Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 105(4):394–402
  15. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG (1996) Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 148(5):1375–1380
  16. Sato F, Shimada Y, Watanabe G, Uchida S, Makino T, Imamura M (1999) Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br J Cancer 80(9):1366–1372. doi:
  17. Sterlacci W, Fiegl M, Hilbe W, Jamnig H, Oberaigner W, Schmid T, Augustin F, Auberger J, Obermann EC, Tzankov A (2010) Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol 5(9):1325–1336. doi:
  18. Lin Q, Li M, Shen ZY, Xiong LW, Pan XF, Gen JF, Bao GL, Sha HF, Feng JX, Ji CY, Chen M (2010) Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer. Jpn J Clin Oncol 40(7):670–676. doi:
  19. Al-Saad S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, Busund LT (2008) The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 99(9):1476–1483. doi:
  20. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18(4):705–719
  21. Rothberg BEG, Bracken MB (2006) E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res Treat 100(2):139–148. doi:
  22. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834
  23. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27(5):335–371
  24. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
  25. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA, Franklin WA (2002) High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 20(10):2417–2428
  26. Choi YS, Shim YM, Kim SH, Son DS, Lee HS, Kim GY, Han J, Kim J (2003) Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer. Eur J Cardiothorac Surg 24(3):441–449
  27. Sulzer MA, Leers MP, van Noord JA, Bollen EC, Theunissen PH (1998) Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med 157(4 Pt 1):1319–1323
  28. Gogali A, Charalabopoulos K, Zampira I, Konstantinidis AK, Tachmazoglou F, Daskalopoulos G, Constantopoulos SH, Dalavanga Y (2010) Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers. Chest 138(5):1173–1179. doi:
  29. Charalabopoulos K, Gogali A, Dalavaga Y, Daskalopoulos G, Vassiliou M, Bablekos G, Karakosta A, Constantopoulos S (2006) The clinical significance of soluble E-cadherin in nonsmall cell lung cancer. Exp Oncol 28(1):83–85
  30. Ruiz MIG, Floor K, Steinberg SM, Grunberg K, Thunnissen FB, Belien JA, Meijer GA, Peters GJ, Smit EF, Rodriguez JA, Giaccone G (2009) Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br J Cancer 100(1):145–152. doi:
  31. Yu J, Shi R, Zhang D, Wang E, Qiu X (2011) Expression of integrin-linked kinase in lung squamous cell carcinoma and adenocarcinoma: correlation with E-cadherin expression, tumor microvessel density and clinical outcome. Virchows Archiv 458(1):99–107. doi:
  32. Ono K, Uramoto H, Hanagiri T (2010) Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC. Anticancer Res 30(9):3273–3278
  33. Ucvet A, Kul C, Gursoy S, Erbaycu AE, Kaya SO, Dinc ZA, Yucel N (2011) Prognostic value of epithelial growth factor receptor, vascular endothelial growth factor, E-cadherin, and p120 catenin in resected non-small cell lung carcinoma. Arch Bronconeumol 47(8):397–402. doi:
  34. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, Takenoyama M, Hanagiri T, Oyama T, Yasumoto K (2010) Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer 70(3):320–328. doi:
  35. Huang C, Liu D, Masuya D, Nakashima T, Kameyama K, Ishikawa S, Ueno M, Haba R, Yokomise H (2005) Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 92(7):1231–1239. doi:
  36. Tamura M, Ohta Y, Tsunezuka Y, Matsumoto I, Kawakami K, Oda M, Watanabe G (2005) Prognostic significance of dysadherin expression in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 130(3):740–745. doi:
  37. Deeb G, Wang J, Ramnath N, Slocum HK, Wiseman S, Beck A, Tan D (2004) Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. Mod Pathol 17(4):430–439. doi:
  38. Nakashima T, Huang C, Liu D, Kameyama K, Masuya D, Kobayashi S, Kinoshita M, Yokomise H (2003) Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients. Br J Cancer 88(11):1727–1733. doi:
  39. Hirata T, Fukuse T, Naiki H, Wada H (2001) Expression of E-cadherin and lymph node metastasis in resected non-small-cell lung cancer. Clin Lung Cancer 3(2):134–140
  40. Lee YC, Wu CT, Chen CS, Hsu HH, Chang YL (2002) The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated non-small cell lung cancers of 3 cm or less in size. J Thorac Cardiovasc Surg 123(3):502–507
  41. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K (2000) Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 6(12):4789–4796
  42. Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, Yokomise H (2001) E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann Thorac Surg 71(3):949–954 (discussion 954–945)
  43. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350(4):351–360. doi:
  44. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (adjuvant Navelbine international trialist association [ANITA]): a randomised controlled trial. Lancet Oncol 7(9):719–727. doi:
  45. Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM, Birchmeier W (1993) Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 120(3):757–766
  46. Bohm M, Totzeck B, Birchmeier W, Wieland I (1994) Differences of E-cadherin expression levels and patterns in primary and metastatic human lung cancer. Clin Exp Metastasis 12(1):55–62
  47. Takeichi M (1990) Cadherins: a molecular family important in selective cell–cell adhesion. Annu Rev Biochem 59:237–252. doi:
  48. Kowalski PJ, Rubin MA, Kleer CG (2003) E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res BCR 5(6):R217–R222. doi:
  49. Mitselou A, Batistatou A, Nakanishi Y, Hirohashi S, Vougiouklakis T, Charalabopoulos K (2010) Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites. Histol Histopathol 25(10):1257–1267
  50. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T (2000) Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6(10):4055–4063
  51. Wang Q, Gu D, Wang M, Zhang Z, Tang J, Chen J (2011) The E-cadherin (CDH1) −160C > A polymorphism associated with gastric cancer among Asians but not Europeans. DNA Cell Biol 30(6):395–400. doi:
  52. Begg CB, Berlin JA (1988) Publication bias: a problem in interpreting medical data. J R Stat Soc Ser A 151:419–463
  53. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67(19):9066–9076. doi:
  54. Fedor-Chaiken M, Hein PW, Stewart JC, Brackenbury R, Kinch MS (2003) E-cadherin binding modulates EGF receptor activation. Cell Commun Adhes 10(2):105–118
  55. Andl CD, Rustgi AK (2005) No one-way street: cross-talk between e-cadherin and receptor tyrosine kinase (RTK) signaling: a mechanism to regulate RTK activity. Cancer Biol Ther 4(1):28–31
  56. Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR (2004) E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 23(8):1739–1748. doi:
  57. Al Moustafa AE, Yen L, Benlimame N, Alaoui-Jamali MA (2002) Regulation of E-cadherin/catenin complex patterns by epidermal growth factor receptor modulation in human lung cancer cells. Lung Cancer 37(1):49–56
• 作者单位：1. Department of Respiratory Medicine, Jiangsu Province Geriatric Hospital, Jiangsu Province Geriatric Institute, 30 Luojia Road, Nanjing, 210024 China2. Department of Respiratory Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China3. First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, China4. Department of Neurology, Jiangsu Province Geriatric Hospital, Jiangsu Province Geriatric Institute, Nanjing, China
• ISSN：1573-4978

文摘

E-cadherin has been implicated in invasiveness and metastasis. However, the clinical prognostic value of decreased E-cadherin expression in patients with non-small cell lung cancer (NSCLC) remains unsettled. A meta-analysis of eligible studies was performed to quantitatively review the correlation of decreased E-cadherin expression with survival in patients with NSCLC. Thirteen studies, including 2,274 patients, were subjected to final analysis. The rate of decreased E-cadherin expression was 47.6 % overall and 41.4 % for stage I disease. The combined hazard ratio (HR) was 1.41 (95 % CI 0.18–1.65; P = 0.001), indicating that decreased E-cadherin expression had an unfavorable impact on the survival of patients with NSCLC. Further, in the stratified analysis by ethnicity, the combined HR in Asians was 1.49 (95 % CI 1.27–1.71) and in non-Asians was 1.01 (95 % CI 1.00–1.02). However, when only the stage I studies were considered, the combined HR was 1.19 (95 % CI 0.90–1.47; P = 0.576), suggesting that decreased E-cadherin expression has no impact on survival. Decreased E-cadherin expression was associated with poor survival in patients with NSCLC, especially among Asians, but was not significantly correlated with survival for stage I NSCLC patients.